Maxim Group Analysts Give Can Fite Biopharma (CANF) a $7.00 Price Target

Maxim Group set a $7.00 target price on Can Fite Biopharma (NYSEAMERICAN:CANF) in a report published on Monday, January 8th. The brokerage currently has a buy rating on the biotechnology company’s stock.

“Weeks after the announcement of enrollment of the first patient in the P3 ACRobat study of Piclidenoson in RA, Can-Fite has announced a distribution agreement with Gebro Holdings GmBH for distribution in Spain, Switzerland, and Austria upon regulatory approval.”,” Maxim Group’s analyst commented.

Separately, HC Wainwright set a $6.00 target price on Can Fite Biopharma and gave the stock a buy rating in a report on Tuesday, October 31st.

Shares of Can Fite Biopharma (CANF) traded up $0.06 during trading on Monday, hitting $1.88. The stock had a trading volume of 192,000 shares, compared to its average volume of 261,167. The firm has a market cap of $30.30, a price-to-earnings ratio of 6.24 and a beta of 1.37. Can Fite Biopharma has a fifty-two week low of $1.24 and a fifty-two week high of $2.67.

TRADEMARK VIOLATION WARNING: This report was published by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/maxim-group-reiterates-buy-rating-for-can-fite-biopharma-canf/1819029.html.

About Can Fite Biopharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal


Leave a Reply

 
© 2006-2018 BBNS.